A Prospective, Randomized, Double-blind, Multi-center, Dose-ranging Study of the Safety, Tolerability and Efficacy of GSK2251052 in the Treatment of Complicated Intra-abdominal Infections in Adults.

Trial Profile

A Prospective, Randomized, Double-blind, Multi-center, Dose-ranging Study of the Safety, Tolerability and Efficacy of GSK2251052 in the Treatment of Complicated Intra-abdominal Infections in Adults.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 May 2014

At a glance

  • Drugs Epetraborole (Primary) ; Meropenem
  • Indications Intra-abdominal infections
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 Oct 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
    • 05 Oct 2012 Status changed from suspended to discontinued, according to an Anacor media release.
    • 13 Apr 2012 Actual patient number (15) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top